Specifically, this phase I trial aimed to determine the safety and toxicity of the combination of AZD2281 (KU-0059436) and carboplatin in patients with recurrent BRCA1/2-associated or familial breast and ovarian cancer, recurrent low-genetic-risk serous ovarian cancer, and recurrent low-genetic-risk triple-negative breast cancer. This evidence concerns the gene BRCA1 and ovarian serous adenocarcinoma.